There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2 R beta & IL-2 R alpha & IL-2 R gamma

IL-2 R beta & IL-2 R alpha & IL-2 R gamma

Brief Information

Target Synonym:T-cell growth factor,IL2,Interleukin 2,T Cell Growth Factor,Aldesleukin,IL-2,TCGF,Involved In Regulation Of T-Cell Clonal Expansion,Interleukin-2,Lymphokine
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data


Human IL-2RB&IL-2RA&IL-2RG, Fc Tag&Fc Tag (Cat. No. ILG-H5257) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 40.6 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).


Loaded Rat IL-2RB&IL-2RA&IL-2RG, His Tag&Twin-Strep Tag (Cat. No. ILG-R5223) on NTA Biosensor, can bind Human IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 1.16 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

IL-2 R beta & IL-2 R alpha & IL-2 R gamma Molecule Synonym Name

IL-2 R beta & IL-2 R alpha & IL-2 R gamma

IL-2 R beta & IL-2 R alpha & IL-2 R gamma Molecule Background

Both Interleukin-2 receptor subunit beta and Interleukin-2 receptor subunit gamma are receptor for interleukin-2. Common subunit for the receptors for a variety of interleukins. Interacts with SHB upon interleukin stimulation. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. IL2R exists in 3 different forms: a high affinity dimer, an intermediate affinity monomer (beta subunit), and a low affinity monomer (alpha subunit). The high and intermediate affinity forms also associate with a gamma subunit.

IL-2 R beta & IL-2 R alpha & IL-2 R gamma References

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Recombinant Human Interleukin-2 Injection (Beijing Four Rings Biopharmaceutical) Approved Beijing Four Rings Bio-Pharmaceutical Co Ltd 新德路生 Mainland China Thrombocytopenia Beijing Four Rings Bio-Pharmaceutical Co Ltd 1997-01-01 Thrombocytopenia Details
Thalidomide NSC-66847; NSC-527179; K-17; VP-02 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Japan Leprosy, Lepromatous Fujimoto Pharmaceutical 1982-01-01 HIV Infections; Spondylitis, Ankylosing; Myelodysplastic Syndromes; Idiopathic Pulmonary Fibrosis; Multiple Myeloma; HIV Wasting Syndrome; Erythema Nodosum; Leprosy, Lepromatous; Carcinoma, Hepatocellular Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Human interleukin-2 biosimilar (Amoytop Biotech/BioGeneric Pharma) rHuIL-2 Clinical Xiamen Amoytop Biotech Co Ltd, Biogeneric Carcinoma, Renal Cell; Melanoma Details
HBAI-20 HBAI-20; HBAI-20-CyTuVax Phase 2 Clinical Cytuvax Hepatitis B Details
Bifikafusp alfa L19-IL-2 Phase 3 Clinical Philogen Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Atherosclerosis; Carcinoma, Basal Cell; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma Details
Autologous tumor cell vaccine (NCI) Phase 2 Clinical H Lee Moffitt Cancer Center & Research Institute, National Cancer Institute, Chiron Spa Carcinoma, Renal Cell; Melanoma Details
ITI-1000 ITI-1000 Phase 2 Clinical Immunomic Therapeutics Glioblastoma Details
T20K T-20K Phase 1 Clinical Cyxone Multiple Sclerosis Details
Interleukin-2 gene therapy (St Jude Children's Research Hospital) Phase 1 Clinical St. Jude Children'S Research Hospital, National Cancer Institute Neuroblastoma Details
Darleukin/fibromun L19-IL-2/ L19-TNF-α Phase 3 Clinical Philogen Melanoma Details
S-95007 S-95007 Phase 2 Clinical Servier Immune System Diseases; Inflammation Details
Interleukin-2 inhalation (Immunservice) Phase 3 Clinical Immunservice Carcinoma, Renal Cell Details
TG-4010 VV-MUC-IL2; TG-4010 Phase 2 Clinical Transgene Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BNT-153 BNT-153 Phase 1 Clinical Biontech Se Solid tumours Details
mRNA-6231 mRNA-6231 Phase 1 Clinical Moderna Therapeutics Autoimmune Diseases Details
SHR-1916 SHR-1916 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours Details

This web search service is supported by Google Inc.